Find information on thousands of medical conditions and prescription drugs.

Eligard

Leuprolide is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it intially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF.

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron.

Read more at Wikipedia.org


[List your site here Free!]


German Regulatory Authority Completes Inspection Of Atrix
From Worldwide Biotech, 7/1/03

Atrix Laboratories, Inc. (NASDAQ:ATRX), Fort Collins, Colo., has announced that the German regulatory authority, Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM), has completed a successful inspection of Atrix's manufacturing facility as part of the on-going process of seeking marketing approval for the company's Eligard(R) (leuprolide acetate for injectible suspension) prostate cancer products in Germany and the European community.

In December 2001, Atrix's European marketing partner, MediGene AG, submitted a Marketing Authorization Application (MAA) for Eligard 7.5mg one-month prostate cancer product. In April 2002, a second MAA was submitted for Eligard 22.5mg three-month prostate cancer product. Both submissions are under review for approval in Germany as a reference member state under a mutual recognition process.

David R. Bethune, Atrix's chairman and chief executive officer commented, "The two BfArM inspectors were here for three and a half days going over the facility. We are pleased to report they found it in compliance with Good Manufacturing Practices (GMP)."

Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery. With five unique patented technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, pain management, and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or improve existing products.

For more information call 970-482-5868 or visit http://www.atrixlabs.com.

COPYRIGHT 2003 Worldwide Videotex
COPYRIGHT 2003 Gale Group

Return to Eligard
Home Contact Resources Exchange Links ebay